SR9009

SR9009 also known as Stenabolic is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC₅₀) = 670 nM for Rev-ErbAα and IC₅₀ = 800 nM for Rev-ErbAβ.

Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.